HALO
HALOZYME THERAPEUTICS, INC.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Jul 20 Contract: Halozyme Announces Global Collaboration and License Agreem…
- Sep 9 to Sep 16 ▼ 4 days of insider sells: $8.5M by 2 insiders, avg $107.39
- Sep 18 Halozyme priced an upsized $1.3 billion private offering of 1.50% co…
- Sep 29 ▼ Gilbert Cisneros sold $1,001 - $15,000, last disclosed Oct 13
- Sep 30 ▲ 4 funds open new positions (13F)
- Oct 1 to Oct 8 ▼ 4 days of insider sells: $7.2M by 2 insiders, avg $110.04
- Oct 15 ▼ In a Final Written Decision, the PTAB held all challenged claims (1,…
- Oct 15 ▼ The PTAB issued a Final Written Decision in PGR2025-00030, finding a…
- Nov 5 ▲ Halozyme reported Q3 2026 total revenue of $493M (+39% YoY) and non-…
- Nov 6 ▲ Halozyme announced that Johnson & Johnson received FDA accelerated a…
- Nov 9 ▼ The PTAB issued a final written decision in PGR2025-00042, holding a…
- Nov 11 ▼ Morgan Stanley downgrades
- Nov 13 New insider trade: subscribers see the details Unlock
- Nov 16 New insider trade: subscribers see the details Unlock
Signal stack
Where each data set points today.
- InsidersMIXED
2 insiders sold $15.7M. Excludes 10 subscriber-only trades.
- InstitutionsBULLISH
Q3 2026: 55 added (4 new), 35 trimmed or exited. Largest new: Wasatch Advisors $115.9M, Qube Research & Technologies $13.4M.
- AnalystsBULLISH
13 of 16 rate it Buy or better. Median target $125.00 (+30%).
- Short sellersSTEADY
Short interest −0.0% to 13.65M shares. 6.8 days to cover, ≈12.0% of shares.
- TrendDOWNTREND
16% below its 50-day average.
- SocialQUIET
No Reddit mentions this week. Last mention Oct 23.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| CONGRESS ASSET MANAGEMENT CO | ADD | $251.9M |
| FIRST TRUST ADVISORS LP | ADD | $200.7M |
| WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | TRIM | $178.5M |
| JANE STREET GROUP, LLC | DOUBLED | $167.7M |
| ROYAL LONDON ASSET MANAGEMENT LTD | TRIM | $138.1M |
| Neuberger Berman Group LLC | DOUBLED | $133.2M |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | TRIM | $128.2M |
| WASATCH ADVISORS LP | NEW | $115.9M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
16 analystsPrice is inside the target range. Median implies +30%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 11, 2026 | Morgan Stanley DOWNGRADE | Equal-Weight |
| Nov 6, 2026 | Leerink Partners DOWNGRADE | Market Perform |
| Nov 6, 2026 | Citizens MAINTAIN | Market Outperform |
| Nov 6, 2026 | Evercore ISI Group MAINTAIN | Outperform |
| Nov 6, 2026 | Wells Fargo MAINTAIN | Equal-Weight |
| Nov 3, 2026 | JP Morgan MAINTAIN | Neutral |
Washington
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
| 🔒 Fresh data, subscribers only Nov 16, 2026 | SELL | |
| 🔒 Fresh data, subscribers only Nov 16, 2026 | SELL | |
| 🔒 Fresh data, subscribers only Nov 16, 2026 | SELL | |
| 🔒 Fresh data, subscribers only Nov 16, 2026 | SELL | |
| 🔒 Fresh data, subscribers only Nov 16, 2026 | SELL | |
| 🔒 Fresh data, subscribers only Nov 16, 2026 | EXERCISE | |
| 🔒 Fresh data, subscribers only Nov 16, 2026 | SELL | |
| 🔒 Fresh data, subscribers only Nov 13, 2026 | SELL |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | $2.33 | $2.32–$2.34 | -0.4% | $488.7M |
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
14 filings · 1 press release · 2 bullish · 3 bearish · 1 mixed · 8 neutral- BEARISH PTAB-TRIALNov 9, 2026
The PTAB issued a final written decision in PGR2025-00042, holding all challenged claims (1, 2, 5…
Monitor Halozyme's next steps: appeal to the Federal Circuit, potential reissue/reexamination, and impact on the parallel district court litigation against Merck. The cancellation of this patent may…
- BULLISH PRESS RELEASENov 6, 2026
Halozyme announced that Johnson & Johnson received FDA accelerated approval for RYBREVANT FASPRO…
Monitor J&J's commercial launch execution and any future label expansions for RYBREVANT FASPRO that could further boost ENHANZE royalties. The approval adds a new revenue driver beyond the existing…
- BULLISH 8-KNov 5, 2026
Halozyme reported Q3 2026 total revenue of $493M (+39% YoY) and non-GAAP EPS of $2.39, beating…
The raised guidance and strong royalty growth signal continued momentum from ENHANZE partnered products. The Dutch patent win against Merck protects a key revenue stream. Watch for further patent…
- NEUTRAL PRESS-RELEASEOct 22, 2026
Halozyme Therapeutics, Inc. announced it will report its Q3 2026 results on November 5, 2026.
All HALO filing & press-release reports (15)
- PTAB-TRIAL reportNov 9, 2026
- PRESS-RELEASE reportNov 6, 2026
- 8-K reportNov 5, 2026
- PRESS-RELEASE reportOct 22, 2026
- INST-CLUSTER reportOct 20, 2026
- PTAB-TRIAL reportOct 15, 2026
- PTAB-TRIAL reportOct 15, 2026
- 8-K reportSep 18, 2026
- CLUSTER reportSep 17, 2026
- CLUSTER reportAug 19, 2026
- CLUSTER reportJul 9, 2026
- CLUSTER reportJul 2, 2026
- CLUSTER reportJun 3, 2026
- 8-K reportApr 30, 2026
- DEFA14A reportMar 23, 2026